X

Trial Profile

The effect of dose on safety, tolerability, and immunogenicity of ACAM2000 smallpox vaccine in adults without previous smallpox vaccination

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACAM 2000 (Primary) ; Modified vaccinia Ankara
Indications Smallpox
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

30 Sep 2008 Primary outcome added as reported by ClinicalTrials.gov.
30 Sep 2008 Study completion date has changed from Mar 2003 to Nov 2003 as reported by ClinicalTrials.gov
30 Sep 2008 Planned number of patients changed from 350 to 353 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com